J&J, Health Canada sued over drug death
A C$100 million ($65.7 million) class-action lawsuit has been launchedin Canada against Johnson & Johnson and Health Canada following the death of a 15-year-old girl from a heart attack. Vanessa Young had been taking J&J's gastroesophageal drug Propulsid (cisapride: Marketletter May 21).
Vanessa's father, former Ontario Member of Parliament Terence Young, who is bringing the action, said that there were "probably hundreds of families...who have buried loved ones that have no idea their death was related to Propulsid."
J&J implemented a limited-access program for the drug last year after it was linked to fatalities and evidence that it caused heart rhythm disorders (Marketletter April 3, 2000), but Vanessa's pharmacist had told her inquest that he was unaware of these problems, and that the patient information leaflet made no mention of them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze